DRDO invites EoI to transfer technology of 2-DG drug for bulk production
DRDO invites EoI to transfer technology of 2-DG drug for bulk production

New Delhi: DRDO has sought EoI (Expression of Interest) from Indian pharma companies for manufacturing 2-deoxy-d-glucose. 2-DG is a medicine helpful in treating patients with corona infection. With the help of Dr Reddy Laboratories, DRDO has developed at the Institute of Nuclear Medicine and Allied Sciences. Clinical results of the drug show that the drug's admit corona sits in the molecule hospital to help patients recover quickly. At the same time, the medical oxygen dependence of patients is also reduced.

The results of the clinical trial show that patients who were treated with 2-DG medicine slipped into RT-PCRZ tests. According to the EoI document, pharma companies are to apply for the same before June 17. The application will be examined by the Technical Assessment Committee. Only 15 companies will be given TOT, it will be on first come first served basis.

Any companies involved in this bidding process should have a drug licence to manufacture active pharmaceutical ingredients (API) given by the Drug Licensing Authority. Also, WHO should be a certificate of GMP (Good Manufacturing Practice). The process of making 2-DG using d-glucose is followed through synthetic process. After going through five chemical processes, 2-DG is made from d-glucose.

Whoever gets corona vaccine in this city will get 5% discount on groceries

Covid Vaccine Slow Drive: Tamil Nadu halts vaccination due to shortage

President Ram Nath Kovind expresses grief over Kanpur road accident


रिलेटेड टॉपिक्स
Join NewsTrack Whatsapp group